Endocrinology Drug Market, By Therapy Area (Diabetes Management Drugs (Insulin (short-acting, long-acting, and premixed), Oral Antidiabetics (biguanides, sulfonylureas, thiazolidinediones, etc.), GLP-1 Receptor Agonists, and Other Combination Therapies), Thyroid Disorder Drugs (Hypothyroidism Treatments (levothyroxine and liothyronine) and Hyperthyroidism Treatments (antithyroid drugs and radioiodine therapy adjuncts), Growth Hormone Related Drugs, (Growth Hormone Deficiency Treatments (recombinant growth hormones, etc.) and Acromegaly Treatments (somatostatin analogs, GH receptor antagonists, etc.)) Adrenal Disorder Drugs, (Cushing’s Syndrome Treatments (steroidogenesis inhibitors, pituitary-targeted drugs), Addison’s Disease Treatments (glucocorticoids, mineralocorticoids), and Congenital Adrenal Hyperplasia Drugs), Reproductive Endocrinology Drugs, (Men’s Health (testosterone therapies, anti-androgens) Women’s Health (estrogen therapies, progesterone therapies, etc.), and Fertility Drugs (gonadotropins, ovulation stimulants, etc.)) and Calcium and Bone Metabolism Drugs (Osteoporosis Treatments (bisphosphonates, SERMs, calcitonin, etc.) and Hyperparathyroidism Treatments (calcimimetics, vitamin D analogs, etc.))), By Route of Administration (Oral, Parenteral, Transdermal (patches and gels), Nasal, and Others (e.g., sublingual and rectal)), By Age Group (Pediatric, Adult, and Geriatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User (Hospitals and Clinics, Specialty Endocrine Centers, Ambulatory Surgical Centers (ASCs), Homecare Settings, and Others (Academic and Research Institutes, etc.)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)